Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06587217 · ClinicalTrials.gov registry record · Phase 1
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm
A Phase 1 study of Parkinsonian Signs in Older Persons, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT06587217 is a Phase 1 study of Parkinsonian Signs in Older Persons that has completed, run by University of Michigan. The registered enrollment target is 5 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06587217, a Phase 1 study of Parkinsonian Signs in Older Persons, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that \~20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this open-label study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.
Conditions Studied
Interventions
- DRUG Carbidopa 25 mg
- DRUG Carbidopa-Levodopa 25/100 mg
Study Locations (2)
Michigan
- Domino's Farms - Ann Arbor
- University Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06587217
The ClinicalTrials.gov registry entry for NCT06587217 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinsonian Signs in Older Persons appearing as the primary indexed condition, and to 2 interventions - of which Carbidopa 25 mg is the first listed.
NCT06587217 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06587217 about?
NCT06587217 is a clinical study titled "Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm". Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking imp...
What is the current status of trial NCT06587217?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-10-29. Estimated completion is 2025-04-03.
What conditions does trial NCT06587217 study?
This clinical trial studies the following conditions: Parkinsonian Signs in Older Persons.
What interventions are being tested in trial NCT06587217?
The interventions under investigation include: Carbidopa 25 mg (DRUG), Carbidopa-Levodopa 25/100 mg (DRUG).
Who is sponsoring clinical trial NCT06587217?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06587217 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.